Pediatric Cardiology

, Volume 27, Issue 5, pp 614–617 | Cite as

A Novel Approach Incorporating Sildenafil in the Management of Symptomatic Neonates with Ebstein’s Anomaly

  • Phat Pham
  • Andrew Hoyer
  • Robin Shaughnessy
  • Yuk M. Law
Article

Abstract

The neonatal presentation of Ebstein’s anomaly is a distinct cyanotic lesion for which little can be done other than to maintain ductal patency or perform palliative surgery if improvement does not occur. We report two cases in which sildenafil was introduced to assist previously failed attempts at weaning of prostaglandin.

Keywords

Ebstein’s anomaly Sildenafil Congenital heart disease 

References

  1. 1.
    Atz AM, Munoz RA, Adatia A, Wessel DL (2003) Diagnostic and therapeutic uses of inhaled nitric oxide in neonatal Ebstein’s anomaly. Am J Caridol 91:906–908CrossRefGoogle Scholar
  2. 2.
    Bruckheimer E, Bulbul Z, Pinter E, et al. (1998) Inhaled nitric oxide therapy in a critically ill neonate with Ebstein’s anomaly. Pediatr Cardiol 19:477–479PubMedCrossRefGoogle Scholar
  3. 3.
    Celermajer DS, Bull C, Till JA, et al. (1994) Ebstein’s anomaly: presentation and outcome from fetus to adult. J Am Coll Cardiol 23:170–176PubMedCrossRefGoogle Scholar
  4. 4.
    Celermajer DS, Cullen S, Sullivan ID, et al. (1992) Outcome in neonates with Ebstein’s anomaly. J Am Coll Cardiol 19:1041–1046PubMedGoogle Scholar
  5. 5.
    Chen JM, Mosca RS, Altmann K, et al. (2004) Early and medium-term results for repair of Ebstein anomaly. J Thorac Cardiovasc Surg 127:990–998PubMedCrossRefGoogle Scholar
  6. 6.
    Danielson GK, Driscoll DJ, Mair DD, Warnes CA, Oliver WC (1992) Operative treatment of Ebstein’s anomaly. J Thorac Cardiovasc Surg 104:1195–1202PubMedGoogle Scholar
  7. 7.
    Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43:68S–72SPubMedCrossRefGoogle Scholar
  8. 8.
    Khot UN, Novaro GM, Popovic ZB, et al. (2003) Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 348:1756–1763PubMedCrossRefGoogle Scholar
  9. 9.
    Knott-Craig CJ, Overholt ED, Ward KE, Razook JD (2000) Neonatal repair of Ebstein’s anomaly: indications, surgical technique, and medium-term follow-up. Ann Throac Surg 69:1505–1510CrossRefGoogle Scholar
  10. 10.
    Pflaumer A, Eicken A, Augustin N, Hess J (2004) Symptomatic neonates with Ebstein’s anomaly. J Thorac Cardiovasc Surg 127:1208–1209PubMedCrossRefGoogle Scholar
  11. 11.
    Schulze-Neick I, Hartenstein P, Li J, et al. (2003) Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108:II167–II173PubMedCrossRefGoogle Scholar
  12. 12.
    Ullmann MV, Born S, Sebening C, et al. (2004) Ventricularization of the atrialized chamber: a concept of Ebstein’s anomaly repair. Ann Throac Surg 78:918–924CrossRefGoogle Scholar
  13. 13.
    Wu Q, Huang Z (2004) A new procedure for Ebstein’s anomaly. Ann Thorac Surg 77:470–476PubMedCrossRefGoogle Scholar
  14. 14.
    Yetman AT, Freedom RN, McCrindle BW (1998) Outcome in cyanotic neonates with Ebstein’s anomaly. Am J Cardiol 81:749–754PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Phat Pham
    • 1
  • Andrew Hoyer
    • 1
  • Robin Shaughnessy
    • 1
  • Yuk M. Law
    • 1
  1. 1.Division of Pediatric CardiologyOregon Health & Science UniversityPortlandUSA

Personalised recommendations